| 4.05 0.19 (4.92%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.84  |
1-year : | 5.65 |
| Resists | First : | 4.14 |
Second : | 4.84 |
| Pivot price | 3.49 |
|||
| Supports | First : | 3.27 |
Second : | 2.74 |
| MAs | MA(5) : | 3.67 |
MA(20) : | 3.4 |
| MA(100) : | 3.21 |
MA(250) : | 3.29 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 95 |
D(3) : | 84.7 |
| RSI | RSI(14): 72.8 |
|||
| 52-week | High : | 4.88 | Low : | 2.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TOI ] has closed above the upper band by 13.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 7.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.15 - 4.16 | 4.16 - 4.17 |
| Low: | 3.81 - 3.83 | 3.83 - 3.84 |
| Close: | 4.02 - 4.05 | 4.05 - 4.07 |
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Fri, 01 May 2026
Insiders of Oncology Institute Getting Good Value On Their US$2.00m Investment - Moomoo
Thu, 30 Apr 2026
Oncology Institute (TOI) plans 2026 virtual meeting with board and pay votes - Stock Titan
Mon, 27 Apr 2026
The Oncology Institute will post Q1 results May 7, then host a 5:30 p.m. ET call - Stock Titan
Mon, 27 Apr 2026
The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call - Yahoo Finance
Mon, 20 Apr 2026
Here’s What Powered The Oncology Institute’s (TOI) Gains - Yahoo Finance
Mon, 06 Apr 2026
Oncology Institute taps veteran healthcare lawyer as it scales - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 99 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 20.1 (%) |
| Held by Institutions | 45 (%) |
| Shares Short | 8,300 (K) |
| Shares Short P.Month | 9,080 (K) |
| EPS | -0.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.16 |
| Profit Margin | -12.1 % |
| Operating Margin | -4.9 % |
| Return on Assets (ttm) | -13.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 41.5 % |
| Gross Profit (p.s.) | 0.77 |
| Sales Per Share | 5.08 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -7.5 |
| PEG Ratio | 0 |
| Price to Book value | -25.32 |
| Price to Sales | 0.79 |
| Price to Cash Flow | -16.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|